Global Cell And Gene Therapy Market Size By Therapy Type (Cell Therapy, Gene Therapy), By Therapeutic Class (Cardiovascular Disease, Cancer), By Delivery Method (Vivo therapy, Ex Vivo therapy), and By Geographic Scope And Forecast

Cell And Gene Therapy Market Size And Forecast

Cell And Gene Therapy Market size was valued at USD 14.76 Billion in 2021 and is projected to reach USD 90.96 Billion by 2030, growing at a CAGR of 22.40% from 2023 to 2030.

The cell and gene therapy market's really taking off, fueled by things like more money going into R&D, a growing, but maybe quiet, need for new treatments, and all the excitement around using cells and genes to fight cancer. Plus, the government's being pretty supportive. CGT is like this whole new frontier in battling tough diseases, even rare genetic ones and, you know, cancer. It's seriously the next big thing in life sciences. Now, remember when COVID hit? Well, that slowed down gene therapy trials for a bit in the early 2020s since everyone was focused on COVID. But, if you're looking for the inside scoop, there's this Global Cell And Gene Therapy Market report. It breaks down the whole market – the important parts, what's hot, what's not, who's competing, and what's really making things tick. It's worth a read!

Global Cell And Gene Therapy Market Definition

Cell therapy is the organization of living cells in patients to treat an infection. The source of cells can be autologous or allogeneic, which can be derived from stem cells such as bone marrow, Stem cell treatment is utilized in bone marrow transplantation. Gene treatment is the introduction, removal, or change within the patient’s genetic code to treat a disease. Additionally, it modifies the expression of an individual’s genes or repairs irregular genes. The therapy includes the organization of nucleic acid (DNA- Deoxyribose nucleic acid/RNA-Ribo nucleic corrosive) with carriers called vectors.

Cell and gene therapies, or CGTs, are really changing the game when it comes to patient care. They're tackling diseases that seemed impossible to treat with regular pills or other biological drugs, offering potential cures or major improvements. The FDA has given the thumbs up to over 20 CGTs in the last two decades, but here's the thingthese one-time treatments can be super expensive, ranging anywhere from US$37,500 to a whopping US$2 million per dose. Because of the high costs and the huge hopes patients have for these life-saving drugs, it's crucial that the companies making them offer complete support throughout the whole process. This includes making sure the manufacturing goes smoothly, coordinating everything carefully, and basically removing any roadblocks that could stop patients from getting the treatments they need.

Global Cell And Gene Therapy Market Overview

The COVID-19 effect, which had earlier come about in restrictive control measures including social offense, remote work, and the closure of commercial exercises brought about by operational challenges, is generally to fault for the growth. The companies are continuing their operations and altering to the modern typical while recovering from the effect. Market participants are working difficult to extend their market presence as they consider the critical development openings within the contract improvement of cellular and gene-modified drugs.

It's cool to see how bio manufacturers are teaming up with contract manufacturers – that's really sparking R&D for their potential new treatments! And the rise of some fresh competition, along with the fact that CMO/CDMO services are getting better and better because of the huge demand, is actually boosting market revenue. To speed up making cell and gene therapies, companies are trying out some clever new things. For example, they're looking into using single-use tech in their production process. This is getting popular because it can help improve things while also saving money and speeding up how fast they can make stuff. All these kinds of improvements are expected to really help the market grow in the coming years!

The developing demand for cutting-edge medicines has expanded market competition among participants. Companies that manufacture cell therapies and CDMOs are inking agreements to rush the improvement of their products and procure a competitive edge. Moreover, clinical investigative projects have driven the contract manufacturing segment’s income development. Additionally, an increase in outsourcing the fabricating handle for cell and gene treatment also supports segment development.

However, The improvement has numerous difficulties, including security and efficacy issues, drawn-out clinical consideration protocols, strict administrative systems, and high cell and gene treatment costs. A few critical components include the capacity to simultaneously treat heterogeneous systems with various cells, high-quality exchange effectiveness, low cell harmfulness, single-cell specificity to the expected target, and single-cell specificity.

Market Attractiveness

The image of market attractiveness provided would further help to get information about the region that is majorly leading in the global Cell And Gene Therapy market. We cover the major impacting factors that are responsible for driving the industry growth in the given region.

Porter’s Five Forces

The image provided would further help to get information about Porter’s five forces framework providing a blueprint for understanding the behavior of competitors and a player’s strategic positioning in the respective industry. The porter’s five forces model can be used to assess the competitive landscape in the global Cell And Gene Therapy market, gauge the attractiveness of a certain sector and assess investment possibilities.

Global Cell And Gene Therapy Market Segmentation Analysis

The Global Cell And Gene Therapy Market is Segmented on the basis of Therapy Type, Therapeutic Class, Delivery Method, and Geography.

Cell And Gene Therapy Market, By Therapy Type

• Cell Therapy
• Gene Therapy

Based on Therapy Type,  the market is bifurcated into Cell Therapy, Gene Therapy. Cell therapy is the transfer of entire, living cells inferred from allogeneic or autologous sources, while gene therapy is the introduction, cancellation, or change of the genome to treat disease. The market is made up of the money that businesses make products for cell, and gene treatment makes from the deals of those things.

Cell And Gene Therapy Market, By Therapeutic Class

• Cardiovascular Disease
• Cancer
• Genetic Disorder
• Rare Diseases
• Oncology
• Hematology
• Ophthalmology
• Infectious Disease
• Neurological Disorders

When we look at what kind of diseases are driving the market, it breaks down into areas like Cardiovascular Disease, Cancer, Genetic Disorder, Rare Diseases, Oncology, Hematology Ophthalmology, Infectious Disease, and Neurological Disorders. The market for genetic disorders is really taking off, and that's because we're seeing more and more cases of genetic and chronic diseases. Plus, governments are doing more to help people understand genetic testing and diagnosis. Speaking of hearts, experts are coming up with new ways to find, diagnose, and treat all sorts of heart problems as they dig deeper into the genetic causes of heart and blood vessel diseases. Some researchers are even trying to predict who might be at risk for sudden cardiac death. And, there's work being done to see if certain medications can help people with serious heart conditions avoid or delay the need for surgery.

Cell And Gene Therapy Market, By Delivery Method

• Vivo therapy
• Ex Vivo therapy

Based on Delivery Method,  the market is bifurcated into Vivo therapy, Ex Vivo therapy. the Vivo therapy market is expected to grow exponentially throughout the anticipated period. When it comes to gene treatment, there are two different methodsex vivo and in vivo, setting aside cell treatments. The changed human gene must begin with entering the unhealthy person’s cells for gene treatment to take impact. There are two strategies for doing this; Genetic fabric is provided in vivo to beset cells (cancer cells or other cells) that are still shown inside an individual’s body.

Cell And Gene Therapy Market, By Geography

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa

So, when we look at the Cell And Gene Therapy Market region by region, we're talking about North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. Right now, North America is the big player, and it looks like it's going to stay that way for a while. Why? Well, they've got a pretty friendly regulatory environment, especially in the U.S. The U.S. FDA has set up a system to work with companies developing these therapies early on, which is a big help. Plus, they've got special assignments to help CGTs move along. And, get this, the approval process in the U.S. is getting even better for companies making these products!

Key Players

The “Global Cell And Gene Therapy Market” study report will provide valuable insight with an emphasis on the global market. The major players in the market are McKinsey, Alnylam Pharmaceuticals Inc., Amgen Inc., Biogen Inc., CORESTEM Inc., Dendreon Pharmaceuticals LLC., Helixmith Co. Ltd., JCR Pharmaceuticals Co. Ltd., Kolon TissueGene Inc., Novartis AG, and Pfizer Inc.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide insight to the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Key Developments

• McKinsey will launch a new Digital Capability Center to quicken the development of cell and gene therapies (CGT). The Digital Capability Center will focus on accelerating operational excellence and digital transformations in biopharmaceutical manufacturing. The Digital Capability Center will join McKinsey’s rapidly growing global network of Digital Capability Centers, immersive learning environments that inspire and prepare organizations to deliver sustainable performance improvement from operational-excellence and tech-enabled transformations.
• on october 3, 2022, Alexion’s genomic medicines annuoced the acquisition of LogicBio’s technology, by this acquiestuion they are looking to incorpate knowledgeable team for preclinical development, and team for research and development on rare diseases. LogicBio has developed a number of technical systems for the delivery and insertion of genes to address genetic disorders. Additionally, they will built a platform to improve the creation of viral vectors.
• On October 12, 2022, Moderna disclosed that Merck(MSD) has decided to exercise its $250 million option to co-develop and commercialize PCV mRNA-4157/V940. The vaccine is now being tested in a phase II clinical trial as adjuvant therapy for patients with high-risk melanoma in combination with pembrolizumab, Merck’s programmed cell death protein 1 (PD-1) antibody.
• On October 3, 2022, Pfizer announced that they have successfully purchased Biohaven Pharmaceuticals which is a migraine drug manufacturing company. They recently manufactured NURTEC ODT (rimegepant) which is approved for both acute therapy and episodic migraine prevention in adults. With Pfizer’s global reach and this acquisition, they will be able to provide migraine patients with more treatment alternatives.

Ace Matrix Analysis

The Ace Matrix provided in the report would help to understand how the major key players involved in this industry are performing as we provide a ranking for these companies based on various factors such as service features & innovations, scalability, innovation of services, industry coverage, industry reach, and growth roadmap. Based on these factors, we rank the companies into four categories as Active, Cutting Edge, Emerging, and Innovators.

Report Scope

Top Trending Reports

Research Methodology of Market Research